TELMISARTAN IN LIGHT OF THE LATEST CLINICAL STUDIES: EFFICACY AND PROSPECTS FOR USE

Telmisartan, a representative of the angiotensin II receptor blocker (ARB) class, is a highly effective medicine for the treatment of arterial hypertension, both in monotherapy and in combination. Its uniqueness lies in the longest half-life among ARBs, which ensures stable and long-lasting blood pressure control throughout the day.In addition to its main action, telmisartan has a partial agonistic effect on PPARγ receptors. Unlike full PPARγ agonists (thiazolidinediones), Telmisartan improves metabolic parameters without causing undesirable side effects.Telmisartan is an antagonist of angiotensin II type 1 receptors, which are key in regulating vascular tone, aldosterone production and sympathetic nervous tone. Its partial agonistic activity on PPARγ gives it anti-inflammatory, anti- proliferative and antioxidant properties, making it valuable for the treatment of patients with metabolic disorders, diabetes mellitus, atherosclerosis and cardiovascular complications. Particular attention is paid to the potential of telmisartan in oncology. The drug may exhibit antiproliferative, anti-apoptotic and anti-metastatic effects, which may form the basis for future clinical trials to repurpose the medicine as a potential anti-cancer agent.The multifaceted pharmacological properties of Telmisartan – from antihypertensive and metabolic to anti- inflammatory, cardio-, nephro-, neuro- aыnd anticancer – make it a promising agent for the treatment of a wide range of diseases. The combination of these effects makes it especially valuable for patients with combined cardiovascular and metabolic pathology, and also opens up new possibilities for its therapeutic use outside the boundaries of classical cardiology.